Broadcast Retirement Network Interview: Classifying Aging as a Disease Could Speed FDA Drug Approvals
Insights Amy Baker · January 9, 2023
Rimon attorney Amy Baker sat down with Jeffrey Snyder from the Broadcast Retirement Network to discuss the potential impact of classifying aging as a disease on FDA drug approvals.
Amy Baker is a Partner in Rimon’s Orlando office. Ms. Baker focuses her practice on advising clients in the life sciences industry. Ms. Baker provides regulatory consulting services to life sciences clients, advising them at all stages of their life cycle, from formation through to clinical trials and commercialization. She advises life sciences clients on the wide range of legal issues which may impact them, including growth strategies, emerging technologies, regulatory compliance with the FDCA, as well as FDA and FTC regulations, labeling and advertising compliance, intellectual property and brand protection issues, and privacy, data breach, and cybersecurity concerns. She also works with life sciences clients to facilitate funding for early stage life science and technology companies. Ms. Baker represents life sciences companies in litigation where required. Read more here.